基线与早期治疗MRI模型预测三阴性乳腺癌新辅助化疗免疫治疗后病理完全缓解
本研究回顾性纳入单中心训练集90例及外部测试集29例接受新辅助化疗免疫治疗的三阴性乳腺癌患者,基于治疗前及首周期后MRI特征构建预测病理完全缓解的模型。模型在外部测试集AUC为0.88、敏感度74%、特异度90%,校准良好。
要点
- 早期新辅助化疗免疫治疗后MRI上病灶内非强化成分相对扩大(PE降低)是预测病理完全缓解的最重要特征。
- 治疗前MRI单灶性、早期肿瘤缩小≥37%及PE降低均为病理完全缓解的独立预测因素。
- 模型在外部测试集预测病理完全缓解的AUC为0.88,敏感度74%,特异度90%。
核心结论
- 构建了一个临床实用的模型,用于三阴性乳腺癌患者新辅助化疗免疫治疗早期预测病理完全缓解。
研究设计与样本
- 回顾性研究,训练集为单中心90例女性(平均年龄49岁,2018年1月至2024年9月),外部测试集为公开试验数据29例女性(平均年龄46岁,日期范围不可得);均于治疗前及首周期后行乳腺MRI(含DCE序列)。
关键影像表现/征象
- 早期新辅助化疗免疫治疗后百分比强化(PE)降低代表病灶内非强化成分相对扩大的半定量评估。
- 治疗前MRI单灶性肿瘤与病理完全缓解独立相关(OR=7.2,p=.001)。
- 早期新辅助化疗免疫治疗后MRI肿瘤缩小≥37%(OR=9.7,p<.001)及PE降低(OR=9.7,p<.001)为病理完全缓解独立预测因素。
诊断标准与关键数值
- 外部测试集中模型预测病理完全缓解的AUC为0.88,敏感度74%,特异度90%。
- 外部测试集校准曲线显示模型预测与观察到的病理完全缓解结局高度一致,Hosmer-Lemeshow检验示模型拟合满意(p=.67)。
临床应用与阅片要点
- 模型基于治疗前及首周期后MRI特征,可早期预测新辅助化疗免疫治疗后的病理完全缓解。
- SHAP分析中PE降低的全局重要性最高(平均绝对SHAP值0.286),其次为ETS(0.233)和单灶性(0.228)。
- 作者指出该模型有助于及时调整临床方案,对缓解者优化降阶梯策略,对无缓解者提示治疗调整。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype lacking targeted therapies. Neoadjuvant chemoimmunotherapy (NACI) improves pathologic complete response (pCR) rates, although patient selection is challenging. OBJECTIVE. The purpose of the study was to develop and test a model incorporating baseline and early-treatment MRI features, including dynamic contrast enhancement (DCE) features, for predicting pCR in patients with TNBC undergoing NACI. METHODS. This retrospective study included patients with TNBC undergoing NACI who underwent breast MRI examinations, including DCE sequences, before treatment and after the first treatment cycle (i.e., early NACI) from a single-center training set of 90 women (mean age, 49 years; January 2018 to September 2024) and an external test set of 29 women (mean age, 46 years; date range unavailable) from publicly available trial data. Two radiologists evaluated the MRI features including percentage enhancement (PE) reduction, representing a semiquantitative assessment of relative expansion of intralesional nonenhancing components after early NACI. A model for predicting pCR on definitive surgery after NACI completion was constructed in the training set using independent predictors from multivariable logistic regression analysis and was evaluated in the external test set. Shapley additive explanations (SHAP) analysis was used to identify features' contributions to model predictions in the training set. RESULTS. Independent predictors of pCR in the training set were tumor unifocality (OR = 7.2, p = .001) on pretreatment MRI and early tumor shrinkage (ETS) of 37% or greater (OR = 9.7, p < .001) and PE reduction (OR = 9.7, p < .001) on early-NACI MRI. A model incorporating these parameters achieved in the external test set an AUC of 0.88, sensitivity of 74%, and specificity of 90% for predicting pCR. In the external test set, calibration curves showed strong concordance between model-predicted and observed pCR outcomes, and the Hosmer-Lemeshow test showed satisfactory model fit (p = .67). In the SHAP analysis, the global importance for model predictions was highest for PE reduction (mean absolute SHAP value, 0.286), followed by ETS (mean absolute SHAP value, 0.233) and unifocality (mean absolute SHAP value, 0.228). CONCLUSION. A clinically practical model was created for early pCR prediction in patients undergoing NACI for TNBC. CLINICAL IMPACT. This MRI-based predictive model could facilitate timely tailoring of clinical regimens after immunotherapy initiation by informing optimal deescalation strategies for responders while prompting therapeutic adaptations for nonresponders.
引用
- Liu B, Wu L, Liu C, et al. Baseline and Early Treatment MRI Model for Predicting Complete Pathologic Response to Neoadjuvant Chemoimmunotherapy in Patients With Triple-Negative Breast Cancer. AJR Am J Roentgenol. 2025. PMID: 40736162. doi:10.2214/AJR.25.33178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。